MYGN Stock Overview
A genetic testing and precision medicine company, develops genetic tests in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.67 |
| 52 Week High | US$29.30 |
| 52 Week Low | US$12.04 |
| Beta | 1.89 |
| 1 Month Change | -7.32% |
| 3 Month Change | -28.94% |
| 1 Year Change | -40.43% |
| 3 Year Change | -49.62% |
| 5 Year Change | -39.72% |
| Change since IPO | 135.72% |
Recent News & Updates
Myriad Genetics: Navigating Through A Setback
Jan 16An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Jan 08
Recent updates
Myriad Genetics: Navigating Through A Setback
Jan 16An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Jan 08Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 13Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?
Nov 02Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge
Nov 02Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?
Sep 20Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking
Aug 30Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?
Jul 17Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?
Jun 05Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 11Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 09Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Mar 28An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued
Feb 02Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Jan 31Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price
Dec 18Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?
Aug 07Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Apr 13Shareholder Returns
| MYGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.2% | 1.8% | -0.8% |
| 1Y | -40.4% | -2.1% | 22.7% |
Return vs Industry: MYGN underperformed the US Biotechs industry which returned -2.2% over the past year.
Return vs Market: MYGN underperformed the US Market which returned 22.6% over the past year.
Price Volatility
| MYGN volatility | |
|---|---|
| MYGN Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MYGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MYGN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,700 | Paul Diaz | www.myriad.com |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| MYGN fundamental statistics | |
|---|---|
| Market cap | US$1.15b |
| Earnings (TTM) | -US$116.00m |
| Revenue (TTM) | US$823.60m |
1.4x
P/S Ratio-9.9x
P/E RatioIs MYGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYGN income statement (TTM) | |
|---|---|
| Revenue | US$823.60m |
| Cost of Revenue | US$254.10m |
| Gross Profit | US$569.50m |
| Other Expenses | US$685.50m |
| Earnings | -US$116.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 69.15% |
| Net Profit Margin | -14.08% |
| Debt/Equity Ratio | 5.3% |
How did MYGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 11:50 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Myriad Genetics, Inc. is covered by 43 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |